BesifloxacinThird Party Manufacturing in India

Besifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, which are essential enzymes required for bacterial DNA replication, transcription, repair, and recombination. It binds to these targets to help the body eradicate susceptible bacterial pathogens causing superficial ocular infections. Unlike older fluoroquinolones, it exhibits balanced dual-targeting activity, delaying the development of bacterial resistance. It is highly effective and well-tolerated.

Therapeutic Uses

• Bacterial Conjunctivitis: Indicated for the topical treatment of purulent bacterial conjunctivitis caused by susceptible isolates.
• Ocular Surface Infections: Prescribed for broad-spectrum management of external eye infections prior to and after ophthalmic surgeries.

Why Manufacturers Choose Besifloxacin

Besifloxacin third party manufacturing in India provides a highly lucrative opportunity for companies aiming to capture the premium ophthalmic antibiotic sector. Because it is a fluoroquinolone reserved primarily for ophthalmic use, it maintains low resistance rates and high clinical efficacy. Our partner facilities are WHO-GMP certified, utilizing advanced aseptic suspension manufacturing lines to maintain uniform particle distribution. Partnering with Celesta for this advanced formulation ensures your brand enters the market with premium quality standards that strictly adhere to WHO-GMP regulations.